Pluristem Therapeutics

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a biotechnology company that is developing off-the-shelf cell therapies for a variety of human diseases. Pluristem’s cell products are derived from human placentas, traditionally left to be medical waste following childbirth. Pluristem then expands these placental-derived cells with the use of a unique, proprietary, three-dimensional (3D) technology platform that insures the efficient, controlled, mass production of the Company’s cell therapy products, termed PLacental eXpanded (PLX) cells. PLX cells act by secreting therapeutic chemokines, cytokines and growth factors in response to signals produced by inflammatory and ischemic conditions within the body. PLX cells are readily available and require no tissue matching prior to administration.